TUBEROUS SCLEROSIS COMPLEX RESEARCH PROGRAM (TSCRP)





MISSION: Support innovative and high-impact research that promotes discoveries in TSC, from mechanistic insights to clinical application across all ages, by fostering new ideas and investigators for the benefit of Service Members, their beneficiaries, and the American public



TSCRP Fiscal Year 2023 (FY23) Funding Mechanisms



Exploration - Hypothesis Development Award (EHDA)

\$150K



New-to-the-Field
Investigator (IDA-NFI)

\$500K



Idea Development Award Established Investigator (IDA-EI)

\$500K



Clinical Translational Research Award (CTRA)

\$1M



Clinical Translational Research Award Partnering PI Option (CTRA-PPIO)

^{\$}1.15M

Clinical Translational Research Award

- The CTRA supports studies that will move promising, well-founded preclinical and/or clinical research findings closer to clinical application, including diagnosis, prognosis, or treatment of Tuberous Sclerosis Complex (TSC).
- Collaborations between clinicians and research scientists are strongly encouraged.

Deadlines

8 June 2023

7 July 2023

August 2023

November 2023

Letter of Intent

Full Applications Due

Peer Review

Programmatic Review

TSCRP FY23 Focus Areas



Understanding, **preventing**, and **treating** the features of TSC-Associated Neuropsychiatric Disorders and reducing their impact, including pharmacological, behavioral, and surgical interventions



Strategies for **eradicating tumors** associated with TSC and TSC-associated **lymphangioleiomyomatosis (LAM)**, including gaining a deeper mechanistic understanding of the tumor microenvironment, TSC signaling, and mTOR-independent pathways



Preventing epilepsy, **improving** treatment, and **mitigating** neurodevelopmental adverse outcomes associated with TSC-related seizures



Developing, **assessing**, and **testing** emerging technologies including imaging and molecular therapeutic strategies, such as gene therapy, to improve outcomes of TSC

